krn-7000 and Leukemia--Lymphocytic--Chronic--B-Cell

krn-7000 has been researched along with Leukemia--Lymphocytic--Chronic--B-Cell* in 2 studies

Other Studies

2 other study(ies) available for krn-7000 and Leukemia--Lymphocytic--Chronic--B-Cell

ArticleYear
Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
    Clinical immunology (Orlando, Fla.), 2017, Volume: 183

    Invariant natural killer T (iNKT) cells are cytotoxic T cells that respond to glycolipid antigens presented by CD1d. Therapeutic activation of iNKT cells with α-galactosylceramide (α-GalCer) can prevent and reverse tumor growth in mice and clinical trials involving α-GalCer-stimulated iNKT cells are ongoing in humans. B cells express CD1d, however, we show that CD1d expression is reduced on B cells from patients with chronic lymphocytic leukemia (CLL). B cells from CLL patients pulsed with α-GalCer failed to stimulate cytolytic degranulation by iNKT cell lines, but could present the more potent glycolipid analogue, 7DW8-5. Retinoic acid receptor-α (RAR-α) agonists induced CD1d expression by CLL B cells, restoring their ability to present α-GalCer to CD8α

    Topics: Aged; Aged, 80 and over; Antigen Presentation; Antigens, CD1d; Antineoplastic Agents; B-Lymphocytes; Benzoates; CD8-Positive T-Lymphocytes; Female; Galactosylceramides; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Natural Killer T-Cells; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Tretinoin

2017
Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.
    Haematologica, 2013, Volume: 98, Issue:3

    Invariant natural killer T cells recognize glycolipid antigens such as α-galactosylceramide presented by CD1d. In preclinical models of B-cell malignancies, α-galactosylceramide is an adjuvant to tumor vaccination, enhancing tumor-specific T-cell responses and prolonging survival. However, numerical and functional invariant natural killer T-cell defects exist in patients with some cancers. Our aim was to assess this axis in patients with chronic lymphocytic leukemia. The numbers of circulating invariant natural killer T cells and the expression of CD1d on antigen-presenting cells were evaluated in patients with chronic lymphocytic leukemia and age-matched controls. Cytokine profile and in vitro proliferative capacity were determined. Patient- and control-derived invariant natural killer T-cell lines were generated and characterized, and allogeneic and autologous responses to α-galactosylce-ramide-treated leukemia cells were assessed. Absolute numbers and phenotype of invariant natural killer T cells were normal in patients with untreated chronic lymphocytic leukemia, and cytokine profile and proliferative capacity were intact. Chemotherapy-treated patients had reduced numbers of invariant natural killer T cells and myeloid dendritic cells, but α-galactosylceramide-induced proliferation was preserved. Invariant natural killer T-cell lines from patients lysed CD1d-expressing targets. Irradiated α-galactosylceramide-treated leukemic cells elicited allogeneic and autologous invariant natural killer T-cell proliferation, and α-galactosylceramide treatment led to increased proliferation of conventional T cells in response to tumor. In conclusion, the invariant natural killer T-cell and CD1d axis is fundamentally intact in patients with early-stage chronic lymphocytic leukemia and, despite reduced circulating numbers, function is retained in fludarabine-treated patients. Immunotherapies exploiting the adjuvant effect of α-galactosylceramide may be feasible.

    Topics: Antigens, CD1d; Cell Line; Cell Proliferation; Cytokines; Dendritic Cells; Galactosylceramides; Humans; Immunophenotyping; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cells; Natural Killer T-Cells; Phenotype

2013